https://buff.ly/3zdzsWj | @American Conference Institute is hosting their 4th Annual Series on Hatch-Waxman and BPCIA from October 8-24, 2024. This series is a virtual three-week program designed to provide new lawyers and executives for the life sciences industry with a solid foundation for understanding the essentials as well as the intricacies of Hatch-Waxman and BPCIA litigation and regulation. Save 10% with promo code D10-999-PM25 #HatchWaxman #BPCIA #ACIConferences
PM360 Magazine’s Post
More Relevant Posts
-
While the eligibility requirement has always been there, the “framework” is new and impacts life sciences. Come to see what best practices Rolando and his panel have to share!
Rolando Medina will moderate the panel, “Best Practice - Traversing the New Patent Eligibility Framework,” at the Life Sciences Patent Network (LSPN) North America Spring Conference on May 8, 2024. #lspnspring #patent #lifesciences https://bit.ly/4bkOLuc
-
-
In-depth analysis: This key article from #PharmaDeals highlights a 31% decline in licensing deal flow in H1 2023. Read the full analysis in this article “#Licensing Down in H1 2023 as Dealmakers Remain Cautious”, to gain insights into the shifting landscape. #BIOEurope https://bit.ly/3Qgk7ZY
JUST RELEASED: Licensing Down in H1 2023 as Dealmakers Remain Cautious
iqvia.com
-
Sr. Director, Human Resources Leader - Professional Services+ at RSM US LLP and RSM Autism Awareness & Acceptance Leader for US and Canada
RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:
Life sciences industry outlook - Fall 2023
-
Webinar | Hatch-Waxman 2023 Year in Review | Fish & Richardson - JDSupra: The Hatch-Waxman Act, signed nearly 40 years ago, aimed to balance the access to lower-cost prescription drugs and the protection of pharmaceutical innovations. Its legal landscape continues to evolve, impacting branded and generic drug developers through court decisions and regulatory agencies. Join Christina Brown-Marshall and Megan Chacon for an overview on December 7, 2023. - IP topics: Intellectual Property topics! #ip #intellectualproperty #copyright
Webinar | Hatch-Waxman 2023 Year in Review
https://www.jdsupra.com/
-
RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:
Life sciences industry outlook - Fall 2023
-
RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:
Life sciences industry outlook - Fall 2023
-
RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:
Life sciences industry outlook - Fall 2023
